 |
|
Placebo study frames depression treatment puzzle
August 01, 2006Brain activity predicts treatment results before medication begins
Treating major depression can be quite a puzzle, and a newly published UCLA study suggests medication is just one of many potential pieces.
Published in the August 2006 edition of the American Journal of Psychiatry, the study used electroencephalogram (EEG) measurements to demonstrate an association between eventual clinical outcome and regional changes in brain activity during a placebo lead-in phase prior to antidepressant treatment.
The findings suggest that factors such as patient beliefs and expectations, doctor-patient relationships, or treatment history help complete the treatment picture.
In this study, all subjects received blinded treatment with placebo for one week prior to receiving antidepressant medication. A "placebo lead-in" phase is commonly used to familiarize patients with study procedures and to minimize the effect of any pre-existing treatment for depression. The placebo lead-in includes patient care, participation and treatment with placebo; the clinical impact is largely unknown.
This study is the first to assess the relationship between brain changes during the placebo lead-in phase and later clinical outcome of antidepressant treatment.
"Treatment results appear to be predicted, in part, by changes in brain activity found during placebo lead-in-prior to the actual use of antidepressant medication," said lead author Aimee M. Hunter, a research associate at the Semel Institute for Neuroscience and Human Behavior at UCLA. "More research is needed to identify the impact of other non-drug factors that affect brain activity and clinical improvement in patients receiving antidepressant treatment." Semel Institute researchers examined data from 51 adults with major depression who were involved in two independent, double-blind placebo-controlled trials.
Quantitative EEG cordance measures were taken at baseline and at the end of the placebo lead-in period. Cordance is a quantitative EEG (QEEG) imaging technique developed at UCLA to measure brain function. Measurements are performed by placing recording electrodes on the scalp. The electrodes connect to the body through conductive paste or gel. It does not hurt and involves no radioactivity. The electrodes are connected to a computer, which measures the signals coming from the brain and processes them into colorful patterns.
Relationships between regional cordance changes at the end of the placebo lead-in period and clinical outcome were examined using a statistical tool called multiple linear regression analysis. Final outcomes were determined using Hamilton Rating Scale for Depression scores.
The study found that decreases in cordance in the prefrontal brain region during the placebo lead-in period were associated with lower depression-scale scores after eight weeks of antidepressant treatment. In subjects randomly assigned to medication, prefrontal changes during placebo lead-in explained 19 percent of the variance in final depression scores.
University of California-Los Angeles
In this study, all subjects received blinded treatment with placebo for one week prior to receiving antidepressant medication. A "placebo lead-in" phase is commonly used to familiarize patients with study procedures and to minimize the effect of any pre-existing treatment for depression. The placebo lead-in includes patient care, participation and treatment with placebo; the clinical impact is largely unknown.
This study is the first to assess the relationship between brain changes during the placebo lead-in phase and later clinical outcome of antidepressant treatment.
"Treatment results appear to be predicted, in part, by changes in brain activity found during placebo lead-in-prior to the actual use of antidepressant medication," said lead author Aimee M. Hunter, a research associate at the Semel Institute for Neuroscience and Human Behavior at UCLA. "More research is needed to identify the impact of other non-drug factors that affect brain activity and clinical improvement in patients receiving antidepressant treatment." Semel Institute researchers examined data from 51 adults with major depression who were involved in two independent, double-blind placebo-controlled trials.
Quantitative EEG cordance measures were taken at baseline and at the end of the placebo lead-in period. Cordance is a quantitative EEG (QEEG) imaging technique developed at UCLA to measure brain function. Measurements are performed by placing recording electrodes on the scalp. The electrodes connect to the body through conductive paste or gel. It does not hurt and involves no radioactivity. The electrodes are connected to a computer, which measures the signals coming from the brain and processes them into colorful patterns.
Relationships between regional cordance changes at the end of the placebo lead-in period and clinical outcome were examined using a statistical tool called multiple linear regression analysis. Final outcomes were determined using Hamilton Rating Scale for Depression scores.
The study found that decreases in cordance in the prefrontal brain region during the placebo lead-in period were associated with lower depression-scale scores after eight weeks of antidepressant treatment. In subjects randomly assigned to medication, prefrontal changes during placebo lead-in explained 19 percent of the variance in final depression scores.
University of California-Los Angeles
Placebo Current Events and Placebo News RSSVioxx trial data shows early cardiovascular risk
Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market.
Drug for erectile dysfunction improves heart function in young heart-disease patients
Heart function significantly improved in children and young adults with single-ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
Your Own Stem Cells Can Treat Heart Disease
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Viagra for women? Drug developed as antidepressant effective in treating low libido
Pooled results from three separate clinical trials of flibanserin, a drug originally created as an antidepressant, show it is effective in treating women with acquired hypoactive sexual desire disorder. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire.
Despite some benefit, drug ads can be harmful to your health
While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits.
The narrow line between love and jealousy
A new study carried out at the University of Haifa has found that the hormone oxytocin, the "love hormone", which affects behaviors such as trust, empathy and generosity, also affects opposite behaviors, such as jealousy and gloating.
CSHL study shows that some malignant tumors can be shut down after all
Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53.
Does green tea prevent cancer? Evidence continues to brew, but questions remain
Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.
Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.
More Placebo Current Events and Placebo News Articles
 |
Battle for the Sun by Placebo 2009 release, the sixth studio album from the British Alt-Rock trio. With a 13 year history that takes in five studio albums, 10 million album sales, breakdowns, clean ups and the dizzy swell of global success, Placebo return with their first album since the release of Meds in 2006. Battle For The Sun was recorded over three months by producer Dave Bottrill (chosen by the band largely because of his work with Tool) in his Toronto studio and mixed in London by Alan Moulder. Battle For The Sun is a startling, alive, vital and boundary-vaulting record that marks a whole new era for a band that were in need of a change. |
 |
Meds by Placebo |
 |
Running Up That Hill (2007 Digital Remaster) Placebo (Primary Contributor) |
 |
Without You I'm Nothing by Placebo This U.K. three-piece's self-titled debut often got compared to Smashing Pumpkins and Rush--Smashing Pumpkins for its unashamed mid-'70s prog-rock allusions and Rush because of singer Brian Molko's unusually high-pitched, almost androgynous voice. In reality, Placebo were far more salacious, downright dirty, and culturally confusing than either. (The band is a mix of American, Swedish, and English, with some Lebanese and Luxembourgian thrown in.) For their second album, Placebo have looked to the late '70s for inspiration, to the sound of early New Order and the Banshees--with a dash of the '90s thrown in: "Brick Shithouse," for example, starts like the most balls-out Prodigy song. If their debut was the sound of a no-holds-barred sexual drug frenzy lasting way into the next day, then... |
 |
Sleeping with Ghosts by Placebo This is the fourth album from Placebo & the follow up to 'Black Market Music', which was released in 2000. With help from Jim Abbiss (Massive Attack, Bjork & UNCLE), 'Sleeping With Ghosts' sees the band moving into a more experimental, electronic territor |
 |
Battle For The Sun (Amazon MP3 Exclusive Version) Placebo (Primary Contributor) |
 |
Battle for the Sun (Limited Edition) (Incl. Bonus DVD) by Placebo Exclusive two disc (CD + NTSC/Region 0 DVD) edition includes one bonus track (the Chinese mix of 'Post Blue' featuring Chinese vocalist Li Ya) plus a bonus DVD containing the 20-minute "making of Battle For The Sun" featurette and the 'For What It's Worth' music video. 2009 release, the sixth studio album from the British Alt-Rock trio. With a 13 year history that takes in five studio albums, 10 million album sales, breakdowns, clean ups and the dizzy swell of global success, Placebo return with their first album since the release of Meds in 2006. Battle For The Sun was recorded over three months by producer Dave Bottrill (chosen by the band largely because of his work with Tool) in his Toronto studio and mixed in London by Alan Moulder. Battle For The Sun is a startling, alive, vital and... |
 |
Once More with Feeling: Singles 1996-2004 by Placebo |
![Pure Morning (Album Version) [Explicit]](http://ecx.images-amazon.com/images/I/51ubN1wXqhL._SL160_.jpg) |
Pure Morning (Album Version) [Explicit] Placebo (Primary Contributor) |
 |
Soulmates Never Die: Live in Paris 2003 Starring: Placebo |
| © 2009 BrightSurf.com |